Iodine I 131 monoclonal antibody CC49-deltaCH2

N/A

Report date: 2026/03/30 20:02:02

Base Information

Drug NameIodine I 131 monoclonal antibody CC49-deltaCH2
Drug Alias Name131I-HuCC49-deltaCH2131I-MOAB CC49-deltaCH2
ClassificationRadiation-emitting products > Nuclides > Iodine > 131IRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionTumor-associated glycoprotein 72 inhibitors
TargetsTumor-associated glycoprotein 72
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsRectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsStomach NeoplasmsRectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A